Abstract Predictive factors for response to regorafenib in recurrent glioblastoma. IDH-wildtype. are scarcely recognized. The objective of this study was to identify molecular predictive factors for response to regorafenib using a clinically available platform. https://www.ashleyshomestores.shop/product-category/queen-platform-bed/